Risk for Severe COVID-19 Not Elevated in Patients with Inflammatory Bowel Disease
Patients with inflammatory bowel disease had a similar risk for and outcomes from coronavirus disease 2019 as those in the general population.
Diarrhea
Microbiome-Based Therapy Looks Promising for Recurrent C difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
Diarrhea in Patients With COVID-19 Suggests Possible Oral-Fecal Transmission Route
The fact that diarrhea is a symptom in the disease course of some patients with COVID-19 highlights the importance of adhering to preventative measures.
Recommendations Developed for Evaluating Chronic Diarrhea
AGA recommends fecal calprotectin, lactoferrin for screening for inflammatory bowel disease.
Rifaximin Beneficial for Abdominal Pain Symptoms in Irritable Bowel Syndrome With Diarrhea
Researchers evaluated the response of rifaximin therapy in patients with IBS-D with abdominal pain symptoms.
Uropathogenic E coli Infection Commonly Manifests As Traveler’s Diarrhea
After molecular testing, half of all travel-acquired ESBL-producing E coli strains qualified as pathogens, despite most being classified as extraintestinal pathogenic or uropathogenic.
Patient’s Diarrhea, Weight Loss Linked to Antihypertensive Med
A recently published report describes the case of a 59-year-old male patient who experienced olmesartan-associated enteropathy (OAE) and highlights the importance of performing thorough medication reviews.
Diarrhea Remains Leading Cause of Global Mortality and Morbidity
A great deal of progress has been made in reducing the burden of diarrheal diseases, but this reduction has not been equal globally.
Novel Blood Test for Irritable Bowel Syndrome Now Available
The test works by measuring levels of anti-cytolethal distending toxin B (CdtB) and anti-vinculin, 2 biomarkers of post-infectious IBS-D and IBS-M.
Rifaximin May Improve Abdominal Pain Symptoms in IBS-D
A 2-week course of treatment with rifaximin for diarrhea-predominant irritable bowel syndrome was found to improve abdominal pain symptoms.
-
Loading...
-
Loading...
Next post in AANP 2018 Annual Meeting
